Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
49results about How to "Reduction in severity and frequency" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Automated method and system for determining the state of well operations and performing process evaluation
InactiveUS6892812B2Efficiently determinedImprove accuracyElectric/magnetic detection for well-loggingSurveyAutomated methodProcess assessment
An automated method and system for determining the state of a drilling or other suitable well operations includes storing a plurality of states for the well operation. Mechanical and hydraulic data is received for the well operation. Based on the mechanical and hydraulic data, one of the states is automatically selected as the state of the well operation. Process evaluation may be performed based on the state of the well operation.
Owner:TDE PETROLEUM DATA SOLUTIONS
Method for monitoring a physiologic parameter of patients with congestive heart failure
A method of monitoring physiological parameters for diagnosis and treatment of congestive heart failure in a patient. The method includes implanting at least one sensing device in a cavity of the patient's cardiovascular system, preferably so that the sensing device passes through and is anchored to a septum of the heart and, to minimize the risk of thrombogenicity, a larger portion of the sensing device is located in the right side of the heart and a smaller portion of the sensing device is located in the left side of the heart. Electromagnetic telecommunication and / or wireless powering of the sensing device is performed with an external readout device. The method can be used to perform effective monitoring, management, and tailoring of treatments for patients suffering from congestive heart failure, as well as many other diseases.
Owner:UIM PRESSURE IMPLANT INC
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
InactiveUS6858598B1Reduce morbidityReduction in severity and frequencyHeavy metal active ingredientsBiocideDNA underwindingIrinotecan
A method of using an MMP inhibitor and optionally radiation therapy, and one or more antineoplastic agents of the topoisomerase class selected from the group consisting of irinotecan and topotecan, as a combination therapy for the treatment of neoplasia is disclosed.
Owner:GD SEARLE & CO
Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation
InactiveUS20030083241A1Inhibition of activationBroad anti-inflammatory activityAntinoxious agentsSomatostatinsOxygen deprivationHypopnea
The invention relates to a method of treating diverse human disorders that may arise, in part, out of sleep hypoxia and oxygen deprivation occurring in the context of sleep apnea / hypopnea disturbances. The disorders that may be treated by the invention comprise gastroesophageal reflux disease (GERD), asthma-associated gastroesophageal reflux (GER), GER-associated asthma, asthma, cardiomyopathy, cardioarrhythmia, congestive heart failure, sudden infant death syndrome, and diverse neurologic conditions. The mode of treatment uses somatostatin receptor ligands (SstRLs), particularly somatostatin-receptor agonists. The invention concerns the method of treatment utilizing, and compositions comprising SstRLs and somatostatin receptor agonists, including agonists of the somatostatin receptor types 2 and 5, particularly, the type 2A receptor (SsR-2A), including octreotide and lanreotide.
Owner:YOUNG CHARLES W
Display substrate, method for manufacturing the same, and display apparatus having the same
InactiveUS20080204618A1Efficiently dissipatedShort circuitStatic indicating devicesNon-linear opticsElectricityEngineering
A display substrate includes a substrate, a guard ring and a connecting line. The substrate includes a plurality of active areas, and each of the active areas has a pixel area and a peripheral area. The guard ring is formed on the substrate to enclose each of the active areas, and is formed from substantially the same layer as a pixel electrode that is formed in a unit pixel. The connecting line is formed from a different layer than the guard ring, to electrically connect the guard ring with pads. The connecting line is formed before forming an organic insulating layer, and thus the frequency and / or severity of patterning defects of the connecting line may be reduced or prevented. Accordingly, short circuits between the pads may be prevented, and the corrosion resistance of the display apparatus may be increased.
Owner:SAMSUNG ELECTRONICS CO LTD
Optimised coding sequence and promoter
ActiveUS20130024960A1Shorten the timeImprove the level ofFactor VIIOrganic active ingredientsLipid storageLipid storage disease
An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and / or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +2
Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent
InactiveUS6916800B2Reduce morbidityReduction in severity and frequencyBiocideHeavy metal active ingredientsCombination therapyMatrix metalloproteinase inhibitor
The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.
Owner:PFIZER INC
Scopolamine to Reduce or Eliminate Hot Flashes, Night Sweats, and Insomnia
InactiveUS20070010550A1Reduction in severity and frequencyAvoid problemsBiocideAnimal repellantsGynecologyHot flashes/flushes
Compositions and methods of treating or preventing hot flashes, night sweats, and / or insomnia in a subject that involve scopolamine are disclosed. For example, methods of treating hot flashes, night sweats, and / or insomnia in a subject that involve transdermal delivery of scopolamine are set forth herein.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Factor viii sequences
ActiveUS20150158930A1Many symptomIncrease of functional factor VIIIFactor VIIBacteriaGene deliveryNucleotide
There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to SEQ ID NO: 4 and which comprises six asparagine residues. Also provided is a functional factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g. haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.
Owner:UCL BUSINESS PLC
Novel drug compositions and dosage forms of topiramate
InactiveUS20050069587A1Promote wound healingReduction in severity and frequencyBiocideCarbohydrate active ingredientsDrugSolubility
The present invention is directed to novel drug compositions and dosage forms comprising said drug compositions. The drug compositions of the present invention comprise a pharmaceutical agent and a solubilizing agent. The drug compositions of the present invention are particularly advantageous for use with low solubility and / or low dissolution rate pharmaceutical agents. The present invention is further directed to methods for manufacturing of said drug compositions and dosage forms. The present invention is further directed to methods of treatment comprising administration of said drug compositions and dosage forms. The present invention further provides topiramate drug compositions, dosage forms and methods of treatment which provide a reduction in the frequency and / or severity of at least one adverse event associated with topiramate treatment.
Owner:ALZA CORP
Sustained-release formulations of topiramate
ActiveUS20080118557A1Reduction in severity and frequencyBiocideSenses disorderOral medicationPharmaceutical drug
Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
Owner:SUPERNUS PHARM INC
Nanoparticle light filtering method and apparatus
ActiveUS20150138661A1Reduce frequencyReduce severitySpectales/gogglesMaterial nanotechnologyNarrow rangeNanoparticle
Implementations of the present invention relate to apparatuses, systems, and methods for blocking, attenuating, or filtering neuroactive wavelengths of the visible light spectrum and reducing or preventing the symptoms affiliated with exposure to those wavelengths. Nanoparticles of a predetermined composition, size, and structure are dispersed in a host medium to create an optical notch filter, thereby attenuating only a narrow range of the visible spectrum.
Owner:UNIV OF UTAH RES FOUND
Combination therapy using anti-EGFR antibodies and anti-hormonal agents
InactiveUS20070202101A1Reduce morbidityReduction in severity and frequencyOrganic active ingredientsBiocideAbnormal tissue growthLymphatic Spread
The invention relates to a combination therapy for the treatment of tumors and tumor metastases, preferably breast and prostate tumors, comprising administration of anti-EGFR (Her1) antibodies and anti-hormonal agents, optionally together with cytotoxic / chemotherapeutic agent. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.
Owner:MERCK PATENT GMBH
Sustained-release formulations of topiramate
ActiveUS20110287099A1Reduction in severity and frequencyBiocideSenses disorderImmediate releaseTopiramate
Owner:SUPERNUS PHARM INC
Nucleic acid molecules encoding modified factor VIII proteins
ActiveUS9447168B2Shorten the timeImprove the level ofFactor VIIPeptide/protein ingredientsGene deliveryNucleotide
There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to SEQ ID NO: 4 and which comprises six asparagine residues. Also provided is a functional factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating hemophilia, e.g. hemophilia A, and a method for the preparation of a parvoviral gene delivery vector.
Owner:UCL BUSINESS PLC
Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent
InactiveUS20050058725A1Reduce morbidityReduction in severity and frequencyBiocideHeavy metal active ingredientsCombination therapyMatrix metalloproteinase inhibitor
Owner:PFIZER INC
Optimised coding sequence and promoter
ActiveUS20150273082A1Shorten the timeImprove the level ofFactor VIIBacteriaLipid storageLipid storage disease
Owner:UCL BUSINESS PLC +2
Nanoparticle light filtering method and apparatus
ActiveUS20150168616A1Reduce frequencyReduce severitySpectales/gogglesMaterial nanotechnologyNarrow rangeNanoparticle
Implementations of the present invention relate to apparatuses, systems, and methods for blocking, attenuating, or filtering neuroactive wavelengths of the visible light spectrum and reducing or preventing the symptoms affiliated with exposure to those wavelengths. Nanoparticles of a predetermined composition, size, and structure are dispersed in a host medium to create an optical notch filter, thereby attenuating only a narrow range of the visible spectrum.
Owner:UNIV OF UTAH RES FOUND
Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
InactiveUS20050037090A1Reduce doseReduce morbidityBiocideHeavy metal active ingredientsCombined Modality TherapyCyclooxygenase
The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a cyclooxygenase-2 inhibitor and an antineoplastic agent.
Owner:MCKEARN JOHN P +5
Compositions for Controlling Neuronal Outgrowth
ActiveUS20140128322A1Reduction in severity and frequencyFacilitate improvement and remediationOrganic active ingredientsNervous disorderMedicineNeuron
Disclosed is a method of promoting neuronal growth by administering IGFBPL-1, or an agent that increases or stabilizes IGFBPL-1 activity to a subject in need thereof, e.g., a subject in need of treating optic nerve degeneration.
Owner:THE SCHEPENS EYE RES INST
Sustained-release formulations of topiramate
ActiveUS20110287103A1Reduction in severity and frequencyOrganic active ingredientsPowder deliveryOral medicationImmediate release
Owner:SUPERNUS PHARM INC
Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
InactiveUS20070093493A1Reduce frequencyReduce severityBiocideUrinary disorderPhosphodiesteraseEccentric hypertrophy
A method of treating symptoms of benign prostatic hypertrophy and a method of treating lower urinary tract symptoms, are disclosed. The method includes administering to a mammal about 1 to about 20 milligrams of an agent that inhibits cyclic guanosine 3,5-monophosphate specific phosphodiesterase type 5.
Owner:LILLY ICOS LLC
Factor viii sequences
ActiveUS20170049859A1Shorten the timeImprove the level ofFactor VIIPeptide/protein ingredientsGene deliveryNucleotide
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +1
Method of treating hearing loss
InactiveUS20100129327A1Reduction in severity and frequencyEncourage adhesionBiocideSenses disorderIn vitroHair loss
The present invention relates to a method of generating cochlear hair cell-like cells in the inner ear of a subject. Preferably, the subject is human and is suffering from sensorineural hearing loss. The invention also relates to a method of generating cochlear hair cell-like cells in vitro and use of the cochlear hair cell-like cells for treating or preventing sensorineural hair loss in a subject.
Owner:OLESKEVICH SHARON +2
Biological Therapeutics for Infection-Relating Disorders or Conditions
ActiveUS20160024186A1Protection from damageSymptoms improvedViral antigen ingredientsImmunoglobulins against virusesTherapeutic antibodySerum ige
The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, serum or plasma, specific antibodies to viral pathogens.
Owner:B&H BIOTECH LLC
COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF alpha
InactiveUS20090035270A1Reduce morbidityReduce frequencyAntibacterial agentsBiocideCombined Modality TherapyCytotoxicity
The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and rumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.
Owner:GRELL MATTHIAS +2
Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
InactiveUS20090196833A1Reduce frequencyReduce severityOrganic active ingredientsBiocideThymidine Phosphorylase DeficiencyMedicine
Topical formulations comprising inhibitors of dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and / or uridine phosphorylase (UP) enzyme inhibitors are provided for the treatment of hand-foot syndrome (HFS) in cancer patients undergoing treatment with 5-FU and 5-FU prodrugs.
Owner:ADHEREX TECH
Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
InactiveUS20080255168A1Effectively block DPD activityReduction in severity and frequencyOrganic active ingredientsBiocideDepressantDPD Inhibitors
Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and / or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient. Also provided are topical formulations comprising DPD, TP and / or UP inhibitors and methods of using same.
Owner:ADHEREX TECH
Administration of recombinant collagen 7 for the treatment of age related disorders
InactiveUS20150343026A1Reduce frequencyReduce severityCyclic peptide ingredientsPharmaceutical non-active ingredientsRelated disorderPathology
The present disclosure provides methods of treating age related disorders through the administration of collagen 7 or the functional fragment or variant thereof
Owner:PHOENIX TISSUE REPAIR INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com